Lidds AB (LIDDS) - Total Liabilities

Latest as of September 2025: Skr491.00K SEK ≈ $52.84K USD

Based on the latest financial reports, Lidds AB (LIDDS) has total liabilities worth Skr491.00K SEK (≈ $52.84K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LIDDS shareholders equity momentum to track the company's year-over-year net asset growth rate.

Lidds AB - Total Liabilities Trend (2010–2024)

This chart illustrates how Lidds AB's total liabilities have evolved over time, based on quarterly financial data. See LIDDS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Lidds AB Competitors by Total Liabilities

The table below lists competitors of Lidds AB ranked by their total liabilities.

Company Country Total Liabilities
NATURENERGIE
SW:NEAG
Switzerland CHF740.50 Million
Israel Opportunity - Energy Resources LP
TA:ISOP-L
Israel ILA259.00K
Wildpack Beverage Inc
V:CANS
Canada CA$141.24 Million
Reco International Group Inc
V:RGI
Canada CA$3.57 Million
Wheeler Real Estate Investment Trust, Inc.
NASDAQ:WHLR
USA $502.61 Million
Pebble Beach Systems Group PLC
LSE:PEB
UK GBX10.61 Million
BLUERUSH Media Group Corp
V:BTV
Canada CA$7.19 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Lidds AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lidds AB (LIDDS) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 3.53 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.33 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.25 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lidds AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lidds AB (2010–2024)

The table below shows the annual total liabilities of Lidds AB from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 Skr1.98 Million
≈ $212.97K
-47.31%
2023-12-31 Skr3.76 Million
≈ $404.21K
-64.47%
2022-12-31 Skr10.57 Million
≈ $1.14 Million
+49.58%
2021-12-31 Skr7.07 Million
≈ $760.52K
-37.99%
2020-12-31 Skr11.40 Million
≈ $1.23 Million
+91.05%
2019-12-31 Skr5.96 Million
≈ $641.91K
+22.76%
2018-12-31 Skr4.86 Million
≈ $522.91K
+36.48%
2017-12-31 Skr3.56 Million
≈ $383.16K
-58.06%
2016-12-31 Skr8.49 Million
≈ $913.69K
+229.98%
2015-12-31 Skr2.57 Million
≈ $276.89K
+10.96%
2014-12-31 Skr2.32 Million
≈ $249.55K
+47.07%
2013-12-31 Skr1.58 Million
≈ $169.68K
-55.24%
2012-12-31 Skr3.52 Million
≈ $379.11K
+107.08%
2011-12-31 Skr1.70 Million
≈ $183.08K
+42.38%
2010-12-31 Skr1.19 Million
≈ $128.59K
--

About Lidds AB

ST:LIDDS Sweden Biotechnology
Market Cap
$361.27K
Skr3.36 Million SEK
Market Cap Rank
#31021 Global
#732 in Sweden
Share Price
Skr0.02
Change (1 day)
+0.00%
52-Week Range
Skr0.01 - Skr0.09
All Time High
Skr19.64
About

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more